CCEL
Cryo Cell International Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
No implied move.
Next report
Last report
—
Largest filed tie
—
13F top-10 QoQ
Top fund weight
Cryo Cell International Inc
Expected move
No implied move.
Next report
Last report
—
Largest filed tie
—
13F top-10 QoQ
Top fund weight
+0.47%
shares held · 10 largest managers
0.00%
CCEL weight · VTI
Bull1
Bear1
No other changes.
No other changes.
| Manager | Value | % base | |
|---|---|---|---|
| SFI | $527,307 | 29.78% | 0.00% |
| Vanguardindex-like | $526,273 | 29.72% | +2.14% |
| Massmutual Trust Co Fsb/adv | $354,202 | 20.00% | 0.00% |
| Geodeindex-like | $147,651 | 8.34% | +6.09% |
| Vanguard Fiduciary Trustindex-like | $74,474 | 4.21% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| SFI | $527,307 | 29.78% | 0.00% |
| Vanguardindex-like | $526,273 | 29.72% | +2.14% |
| Massmutual Trust Co Fsb/adv | $354,202 | 20.00% | 0.00% |
| Geodeindex-like | $147,651 | 8.34% | +6.09% |
| Vanguard Fiduciary Trustindex-like | $74,474 | 4.21% | 0.00% |
No peers for Cryo Cell International Inc yet.
No peers for Cryo Cell International Inc yet.
Annual filing, covered
10-K parsed · Feb 27 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 27 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Tall tick = annual report · Source: EDGAR
No thesis.
Cryo Cell International Inc
4.38
−0.80 · −15.53%
post 5.00 +14.16%
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
—
—